Seer, Inc.

NASDAQ:SEER

Biotechnology

Healthcare
$1.44 +0.29%

+$0.01 today

Market cap
$80.37M
Beta
1.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.26
52W Low $1.65High $2.41

Volume 0.23M

Average 0.32M

SEER Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Seer, Inc.NASDAQ: SEER

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash dips below year-ago levels

Q1 FY2026 net change in cash of $33K fell 99.7% year over year, behind the +162.5% change in trailing-twelve-month net change in cash. Sequentially, it fell 98.6% from the prior quarter.

Context

  • Net change in cash amounted to 40.5% of revenue in FY2025, down 18.7 pp from a year earlier.
  • Net change in cash increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -99.7% toward the trailing-twelve-month pace of +162.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$33K-98.6% QoQ
Last fiscal yearDec 2025
$6.53M-20.9% YoY
LTMMar 2026
-$5.13M+162.5% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-99.7%——
1 year-20.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
6.53M USD
Year-over-year change
-20.9%

Net Change in Cash vs competitors

How SEER compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +162.5% is the 8th highest of 19, against a peer median of -2.5%.
  • Net change in cash amounts to 34.1% of revenue for SEER, versus a peer median of 189.5%.
SEER Competitors
Net Change in Cash for SEER and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$641.62M USD+3223.9%—91.4%
KYMRKymera Therapeutics, Inc.LTM Jun 2026$211.34M USD-178.8%+126.3%201.3%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$81.4M USD+483.5%-31.3%189.5%
PHVSPharvaris N.V.LTM Sep 2026€52.24M EUR-316.8%——
MOLNMolecular Partners AGLTM Mar 2026CHF 41.33M CHF-462.5%+5.2%—
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$36.48M USD+7.5%-8.6%—
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$33.5M USD+811.6%——
LYELLyell Immunopharma, Inc.LTM Mar 2026$29.66M USD+457.2%-35.6%95683.9%
STTKShattuck Labs, Inc.LTM Mar 2026$29.52M USD+295.4%-58.6%2952.1%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$27.89M USD+253.0%—98.8%
NKTXNkarta, Inc.LTM Mar 2026$25.24M USD-87.2%——
SANASana Biotechnology, Inc.LTM Mar 2026$12.33M USD-84.7%-9.5%—
CCCCC4 Therapeutics, Inc.LTM Mar 2026$9.98M USD+126.0%—28.6%
MNOVMediciNova, Inc.LTM Mar 2026$9.24M USD-12.5%-43.5%1549.0%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$7.06M USD+200.5%-55.8%—
SEERSeer, Inc.LTM Mar 2026$5.13M USD+162.5%—34.1%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$1.57M USD-164.9%-61.9%—
PEPGPepGen Inc.LTM Mar 2026$1.48M USD-98.4%-39.0%—
QSIQuantum-Si incorporatedLTM Mar 2026$1.09M USD-93.1%—59.0%
Peer median (excluding SEER) —-2.5%-35.6%189.5%

Competitors are the stored peer set for SEER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(71.17M)(92.97M)(86.28M)(86.6M)(73.6M)
Depreciation & Amortization2.56M3.94M5.58M6.18M7.25M
Deferred Income Tax1.2M0000
Stock-Based Compensation25.93M33.67M34.42M28.21M15.41M
Change in Working Capital(5.87M)(7.09M)(2.72M)(144K)(579K)
Accounts Receivables(2.5M)(2.87M)302K487K277K
Inventory(3.59M)(1.59M)(1.95M)(2.67M)(2.9M)
Accounts Payables1.6M(1.55M)(987K)3.36M1.06M
Other Working Capital(1.38M)(1.07M)(91K)(1.32M)983K
Other Non-Cash Items1.01M1.66M(10.07M)6.25M7.07M
Operating Cash Flow(46.35M)(60.78M)(59.07M)(46.11M)(44.45M)
Capital Expenditures(6.92M)(10.27M)(7.31M)(3.58M)(1.8M)
Acquisitions (Net)163.96M0000
Purchases of Investments(279.96M)(366.27M)(403.09M)(272.93M)(173.17M)
Sales of Investments116M253.65M448.31M342.03M237.81M
Other Investing Activities(163.96M)170K0343K(1.3M)
Investing Cash Flow(170.88M)(122.72M)37.9M65.86M61.55M
Debt Repayment00000
Common Stock Issued102.96M000458K
Common Stock Repurchased(35K)(20K)(13K)(11.82M)(10.2M)
Dividends Paid00000
Other Financing Activities13.71M3.91M465K321K(827K)
Financing Cash Flow116.63M3.89M452K(11.5M)(10.57M)
Effect of Forex Changes00000
Net Change in Cash(100.59M)(179.61M)(20.71M)8.25M6.53M
Free Cash Flow(53.27M)(71.05M)(66.37M)(49.69M)(46.25M)

Seer, Inc.

NASDAQ:SEER

Intrinsic Alpha fair value

Locked

Current Price

$1.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.